指南与共识前列腺癌

美国国家综合癌症网络指南在前列腺癌未选择患者中识别致病性胚系变异的效能:PROCLAIM试验

Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial.
指南 / 共识 · Eur Urol Oncol · 2023-08-12

PROCLAIM试验前瞻性连续纳入美国15个中心958例未选择的前列腺癌患者,多基因癌症 panel 检测发现致病/可能致病性胚系变异(PGV)患病率为7.7%(95%CI 6.2-9.6%)。符合2019年NCCN前列腺癌标准者PGV患病率为8.8%(43/486),不符合者为6.6%(31/472),两组无显著差异(OR 1.38,95%CI 0.85-2.23),现行标准会漏检42%的PGV患者。结论认为应为所有前列腺癌患者提供全面的胚系基因检测。

要点

  • 未选择前列腺癌患者中PGV患病率为7.7%(95%CI 6.2-9.6%),约每13例中1例携带可操作的遗传变异。
  • 符合与不符合2019年NCCN标准者的PGV患病率无显著差异(8.8% vs 6.6%,OR 1.38,95%CI 0.85-2.23)。
  • 现行NCCN标准会漏检42%(31/74,95%CI 31-53%)的PGV患者,且对代表性不足人群预测效能更差。

核心结论

  • 几乎一半携带PGV的前列腺癌患者被现行检测指南漏检,应为所有前列腺癌患者提供全面的胚系基因检测。

研究设计与样本

  • 前瞻性连续纳入美国15个中心2019年10月至2021年8月未选择的前列腺癌患者,进行多基因癌症 panel 检测。
  • 共纳入958例患者,诊断时中位年龄65岁(四分位数60-71岁),627例(65%)为低危或中危疾病(分级组1、2或3)。

主要发现

  • 74例患者(7.7%,95%CI 6.2-9.6%)中检出17个基因的77个PGV。
  • 符合2019年NCCN前列腺癌标准者PGV患病率为8.8%(43/486,95%CI 6.6-12%),不符合者为6.6%(31/472,95%CI 4.6-9.2%),两组无显著差异(OR 1.38,95%CI 0.85-2.23)。
  • 现行标准会漏检42%(31/74,95%CI 31-53%)的PGV患者。
  • 多数PGV(81%,60/74)具有潜在临床可操作性。

关键数值与推荐

  • 2019年NCCN前列腺癌标准在符合者中PGV患病率为8.8%(43/486,95%CI 6.6-12%),在不符合者中为6.6%(31/472,95%CI 4.6-9.2%),OR 1.38(95%CI 0.85-2.23)。
  • 该标准会漏检42%(31/74,95%CI 31-53%)的PGV患者。
  • 该标准在来自代表性不足人群的患者中预测PGV的效能较低。

临床怎么用

  • 作者结论认为应为所有前列腺癌患者提供全面的胚系基因检测。

局限性

  • 局限性包括因非白人PGV患者数量少而无法按个体种族分层分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer (PCa) patients with pathogenic/likely pathogenic germline variants (PGVs) in cancer predisposition genes may be eligible for U.S. Food and Drug Administration-approved targeted therapies, clinical trials, or enhanced screening. Studies suggest that eligible patients are missing genetics-informed care due to restrictive testing criteria. OBJECTIVE: To establish the prevalence of actionable PGVs among prospectively accrued, unselected PCa patients, stratified by their guideline eligibility. DESIGN, SETTING, AND PARTICIPANTS: Consecutive, unselected PCa patients were enrolled at 15 sites in the USA from October 2019 to August 2021, and had multigene cancer panel testing. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Correlates between the prevalence of PGVs and clinician-reported demographic and clinical characteristics were examined. RESULTS AND LIMITATIONS: Among 958 patients (median [quartiles] age at diagnosis 65 [60, 71] yr), 627 (65%) had low- or intermediate-risk disease (grade group 1, 2, or 3). A total of 77 PGVs in 17 genes were identified in 74 patients (7.7%, 95% confidence interval [CI] 6.2-9.6%). No significant difference was found in the prevalence of PGVs among patients who met the 2019 National Comprehensive Cancer Network Prostate criteria (8.8%, 43/486, 95% CI 6.6-12%) versus those who did not (6.6%, 31/472, 95% CI 4.6-9.2%; odds ratio 1.38, 95% CI 0.85-2.23), indicating that these criteria would miss 42% of patients (31/74, 95% CI 31-53%) with PGVs. The criteria were less effective at predicting PGVs in patients from under-represented populations. Most PGVs (81%, 60/74) were potentially clinically actionable. Limitations include the inability to stratify analyses based on individual ethnicity due to low numbers of non-White patients with PGVs. CONCLUSIONS: Our results indicate that almost half of PCa patients with PGVs are missed by current testing guidelines. Comprehensive germline genetic testing should be offered to all patients with PCa. PATIENT SUMMARY: One in 13 patients with prostate cancer carries an inherited variant that may be actionable for the patient's current care or prevention of future cancer, and could benefit from expanded testing criteria.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Shore N, Gazi M, Pieczonka C, et al. Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial. Eur Urol Oncol. 2023. PMID: 37574391. doi:10.1016/j.euo.2023.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。